Mangalam Drugs and Organics Ltd

AI

Mangalam Drugs and Organics Ltd

₹ 27.6 -3.54%
20 Nov - close price
About

Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.[1]

Key Points

Business Overview:[1]
MDOL (formerly Advent Pharma Pvt Ltd) is a part of the Mangalam group. The co manufactures bulk drugs, and organic and inorganic chemicals. It is among the few companies which are World Health Org.approved Indian companies to be associated
with the William J Clinton Foundation (Clinton Foundation) for manufacture of anti-malarial drugs. MDOL supplies artemisinin-based bulk drugs to pharmaceutical companies, for the manufacture of anti-malarial formulations.

  • Market Cap ₹ 43.6 Cr.
  • Current Price ₹ 27.6
  • High / Low ₹ 54.5 / 22.7
  • Stock P/E
  • Book Value ₹ 55.6
  • Dividend Yield 0.00 %
  • ROCE -14.1 %
  • ROE -35.3 %
  • Face Value ₹ 10.0

Pros

  • Stock is trading at 0.50 times its book value

Cons

  • Company has low interest coverage ratio.
  • Promoter holding is low: 35.6%
  • Company has a low return on equity of -11.6% over last 3 years.
  • Debtor days have increased from 45.3 to 63.4 days.
  • Promoter holding has decreased over last 3 years: -14.7%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 (S) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
81.56 97.34 102.24 76.53 79.94 88.71 72.78 57.21 49.54 58.38 67.29 57.12 79.39
79.37 90.36 90.55 68.34 71.24 79.94 62.88 61.83 52.38 59.92 72.91 56.21 80.54
Operating Profit 2.19 6.98 11.69 8.19 8.70 8.77 9.90 -4.62 -2.84 -1.54 -5.62 0.91 -1.15
OPM % 2.69% 7.17% 11.43% 10.70% 10.88% 9.89% 13.60% -8.08% -5.73% -2.64% -8.35% 1.59% -1.45%
0.03 0.00 0.05 0.02 0.14 0.14 0.47 0.14 0.03 0.22 0.09 0.11 0.17
Interest 3.24 3.31 3.95 3.75 3.67 3.49 4.03 4.04 5.03 4.05 3.08 3.68 3.89
Depreciation 3.73 3.63 3.86 3.88 3.97 4.05 4.70 4.48 4.63 4.46 4.66 4.09 4.12
Profit before tax -4.75 0.04 3.93 0.58 1.20 1.37 1.64 -13.00 -12.47 -9.83 -13.27 -6.75 -8.99
Tax % -25.05% -1,150.00% 10.18% -362.07% -124.17% 5.84% 95.73% 6.15% -41.06% 0.00% 1.13% 13.19% -19.80%
-3.56 0.50 3.53 2.68 2.69 1.29 0.06 -13.80 -7.35 -9.84 -13.42 -7.64 -7.21
EPS in Rs -2.25 0.32 2.23 1.69 1.70 0.82 0.04 -8.72 -4.64 -6.22 -8.48 -4.83 -4.56
Raw PDF

(S): Standalone figures, shown where consolidated figures are not available.

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026 TTM
221 295 299 269 228 282 380 451 372 369 318 232 262
200 257 252 222 218 259 327 402 347 351 282 247 270
Operating Profit 20 38 47 47 10 24 53 49 26 17 36 -15 -7
OPM % 9% 13% 16% 17% 4.3% 8% 14% 11% 7% 4.7% 11% -6% -2.8%
0 0 -0 1 0 1 5 0 0 0 1 1 1
Interest 10 9 10 12 9 10 9 11 13 14 15 16 15
Depreciation 4 4 5 7 7 8 9 10 11 15 17 18 17
Profit before tax 6 24 31 29 -6 6 40 28 2 -11 5 -49 -39
Tax % -2% 33% 29% 32% 40% -32% 29% 29% 43% -18% -41% -9%
6 16 22 20 -8 8 28 20 1 -9 7 -44 -38
EPS in Rs 4.66 11.15 14.08 12.57 -5.07 5.21 17.67 12.42 0.80 -5.73 4.25 -28.05 -24.09
Dividend Payout % 0% 0% 0% 4% 0% 0% 0% 0% 0% 0% 0% 0%

(S): Standalone figures, shown where consolidated figures are not available.

Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -2%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -92%
Stock Price CAGR
10 Years: -15%
5 Years: -26%
3 Years: -34%
1 Year: -41%
Return on Equity
10 Years: %
5 Years: %
3 Years: -12%
Last Year: -35%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 13 14 16 16 16 16 16 16 16 16 16 16 16
Reserves 16 47 70 88 80 88 115 135 136 120 133 87 72
78 60 66 69 65 52 70 88 89 107 96 113 90
63 38 38 54 50 75 64 90 117 91 121 99 120
Total Liabilities 170 160 190 227 211 231 264 328 358 334 366 315 298
53 54 93 102 103 101 118 135 142 148 163 155 152
CWIP 0 5 0 0 0 1 6 6 9 8 3 4 0
Investments 0 0 2 0 0 0 0 0 0 0 0 0 0
117 100 95 125 107 128 140 188 206 178 201 156 146
Total Assets 170 160 190 227 211 231 264 328 358 334 366 315 298

(S): Standalone figures, shown where consolidated figures are not available.

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026
14 22 43 25 22 31 28 26 38 4 43 4
-4 -11 -39 -16 -9 -7 -31 -27 -22 -12 -19 -12
-10 -11 -3 -9 -11 -23 3 3 -17 5 -22 6
Net Cash Flow 1 -0 0 -0 1 0 -1 1 -1 -3 1 -2
Free Cash Flow 10 11 3 9 12 24 -4 -2 16 -8 23 -8
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 69% 68% 107% 66% 223% 129% 69% 70% 148% 23% 120% -30%

(S): Standalone figures, shown where consolidated figures are not available.

Ratios

Consolidated / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026
Debtor Days 73 37 45 61 28 52 52 38 46 28 45 63
Inventory Days 134 85 69 132 175 121 85 139 200 185 303 239
Days Payable 128 37 38 82 77 106 63 65 139 99 214 177
Cash Conversion Cycle 79 85 75 111 126 67 74 112 107 113 134 126
Working Capital Days 26 32 19 31 21 10 23 43 38 11 6 -65
ROCE % 16% 29% 31% 25% 2% 11% 27% 18% 6% 8% -14%

(S): Standalone figures, shown where consolidated figures are not available.

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Export Turnover (Foreign Exchange Earned)
INR Lakhs ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Total Employees
Count ・Standalone data
Anti-Malarial API Revenue Share
% of total revenue ・Standalone data
Top Customer Concentration
% of total revenue ・Standalone data
Total Production Volume
Metric Tons (MT) ・Standalone data
R&D Scientists
Count ・Standalone data
Installed Capacity
Tonnes Per Annum (TPA) ・Standalone data
Tenofovir Disoproxil Fumarate Production
Metric Tons (MT) ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
50.31% 50.31% 50.31% 50.30% 50.30% 50.30% 50.30% 50.30% 35.64% 35.65% 35.65% 35.65%
0.10% 0.26% 0.21% 0.11% 0.11% 0.47% 0.53% 0.11% 0.13% 0.32% 0.11% 0.11%
49.59% 49.42% 49.47% 49.58% 49.58% 49.23% 49.16% 49.57% 64.22% 64.03% 64.24% 64.24%
No. of Shareholders 18,61019,17319,31219,50819,67919,69719,72819,88121,22725,14024,46523,991

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls